Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

IL-33: a jack of all trades in the orchestration of respiratory antibacterial immunity

Cellular & Molecular Immunology volume 14, pages 875–877 (2017)Cite this article

Influenza A virus (IAV) is the causative agent of mostly mild to moderate seasonal respiratory infections and several pandemic outbreaks, the most recent of which was reported in 2009. Previous IAV pandemics were associated with an enormous death toll; for example, the 1918 H1N1 pandemic affected hundreds of millions of people globally and resulted in ~50 million deaths.1 Microbiologic analyses of patient samples revealed a strong incidence of bacterial pathogens in fatal complications of viral infection.2 To date, many pieces of epidemiologic and experimental evidence reveal pronounced susceptibility to detrimental bacterial superinfection in IAV-infected individuals. The physiologic mechanisms underlying the fatal synergism between IAV and opportunistic respiratory bacterial pathogens are so far incompletely understood. Among these mechanisms, the depletion3 or dysfunction4 of professional phagocytes, attenuation of antimicrobial production5 or desensitization to microbial-associated molecular patterns (MAMPs)6 are just a few examples indicating the deactivation of airway antimicrobial defense during IAV infection.

Interleukin 33 (IL-33) is one of 11 members of the IL-1 family of cytokines. Although intracellular IL-33 can act as a potent regulator of stimulated and constitutive gene expression, extracellular IL-33 has pleiotropic downstream effects on cells expressing the specific (primary) IL-33 receptor ST2 (for example, fibroblasts, mast cells, T helper 2 (TH2) cells, resident macrophages, DCs, and type 2 innate lymphoid cells (ILC2)).7 Furthermore, IL-33 is released after cellular injury and (after enzymatic processing) can thus act as a conserved endogenous danger molecule, also termed ‘alarmin’.8 IL-33 signaling is reported to have detrimental effects in chronic, non-communicable lung ailments, whereas its role during respiratory infection greatly differs for the various pathogens and the correlating immune responses mounted against them.9 Importantly, the impact of a preceding IAV infection on IL-33 production during secondary bacterial pneumonia and, vice versa, the physiologic effects of IL-33 on the course of the secondary infection have so far not been addressed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Taubenberger JK, Morens DM . 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12: 15–22.

    Article  Google Scholar 

  2. Chien YW, Klugman KP, Morens DM . Bacterial pathogens and death during the 1918 influenza pandemic. N Engl J Med 2009; 361: 2582–2583.

    Article  Google Scholar 

  3. Ghoneim HE, Thomas PG, McCullers JA . Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 2013; 191: 1250–1259.

    Article  CAS  Google Scholar 

  4. Sun K, Metzger DW . Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14: 558–564.

    Article  CAS  Google Scholar 

  5. Robinson KM, McHugh KJ, Mandalapu S, Clay ME, Lee B, Scheller EV et al. Influenza A virus exacerbates Staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production. J Infect Dis 2014; 209: 865–875.

    Article  CAS  Google Scholar 

  6. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008; 205: 323–329.

    Article  CAS  Google Scholar 

  7. Martin NT, Martin MU . Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol 2016; 17: 122–131.

    Article  CAS  Google Scholar 

  8. Enoksson M, Lyberg K, Moller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C . Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 2011; 186: 2523–2528.

    Article  CAS  Google Scholar 

  9. Liew FY, Girard JP, Turnquist HR . Interleukin-33 in health and disease. Nat Rev Immunol 2016; 16: 676–689.

    Article  CAS  Google Scholar 

  10. Robinson KM, Ramanan K, Clay ME, McHugh KJ, Rich HE, Alcorn JF . Novel protective mechanism for interleukin-33 at the mucosal barrier during influenza-associated bacterial superinfection. Mucosal Immunol 2017; In press.

  11. Duvigneau S, Sharma-Chawla N, Boianelli A, Stegemann-Koniszewski S, Nguyen VK, Bruder D et al. Hierarchical effects of pro-inflammatory cytokines on the post-influenza susceptibility to pneumococcal coinfection. Sci Rep 2016; 6: 37045.

    Article  CAS  Google Scholar 

  12. Schliehe C, Flynn EK, Vilagos B, Richson U, Swaminathan S, Bosnjak B et al. The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection. Nat Immunol 2015; 16: 67–74.

    Article  CAS  Google Scholar 

  13. Wills-Karp M, Rani R, Dienger K, Lewkowich I, Fox JG, Perkins C et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med 2012; 209: 607–622.

    Article  CAS  Google Scholar 

  14. Sanders CJ, Vogel P, McClaren JL, Bajracharya R, Doherty PC, Thomas PG . Compromised respiratory function in lethal influenza infection is characterized by the depletion of type I alveolar epithelial cells beyond threshold levels. Am J Physiol Lung Cell Mol Physiol 2013; 304: L481–L488.

    Article  CAS  Google Scholar 

  15. Stegemann-Koniszewski S, Jeron A, Gereke M, Geffers R, Kroger A, Gunzer M et al. Alveolar type II epithelial cells contribute to the anti-Influenza A virus response in the lung by integrating pathogen- and microenvironment-derived signals. MBio 2016; 7.

  16. Cleaver JO, You D, Michaud DR, Pruneda FA, Juarez MM, Zhang J et al. Lung epithelial cells are essential effectors of inducible resistance to pneumonia. Mucosal Immunol 2014; 7: 78–88.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

DB is supported by the German Research Foundation (BR2221/4-1).

Author information

Authors and Affiliations

  1. Infection Immunology Group, Institute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University, Magdeburg, Germany

    Julia D Boehme & Dunja Bruder

  2. Department of Immune Control, Immune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany

    Julia D Boehme & Dunja Bruder

Authors
  1. Julia D Boehme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dunja Bruder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dunja Bruder.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boehme, J., Bruder, D. IL-33: a jack of all trades in the orchestration of respiratory antibacterial immunity. Cell Mol Immunol 14, 875–877 (2017). https://doi.org/10.1038/cmi.2017.53

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cmi.2017.53

Search

Advanced search

Quick links